NRXS Stock Summary and Trading Ideas (Neuraxis | AMEX:NRXS)

Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).

Neuraxis trades on the AMEX stock market under the symbol NRXS.

As of December 29, 2025, NRXS stock price declined to $3.89 with 62,891 million shares trading.

NRXS has a beta of 1.50, meaning it tends to be more sensitive to market movements. NRXS has a correlation of 0.09 to the broad based SPY ETF.

NRXS has a market cap of $41.44 million. This is considered a Sub-Micro Cap stock.

Last quarter Neuraxis reported $811,414 in Revenue and -$.24 earnings per share. This fell short of revenue expectation by $-188,586 and missed earnings estimates by -$.04.

The top ETF exchange traded funds that NRXS belongs to (by Net Assets): VTI, VXF.

NRXS has outperformed the market in the last year with a price return of +62.1% while the SPY ETF gained +15.4%. NRXS has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +30.1% and +46.8%, respectively, while the SPY returned +4.0% and +1.0%, respectively.

NRXS support price is $3.63 and resistance is $4.21 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NRXS shares will trade within this expected range on the day.